Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2012

View Archived Issues

Novel candidate anticancer drugs patented by Portola Pharmaceuticals

Phase II results reported on amatuximab

Phase I trial assesses volasertib combination regimens for solid tumors

New PI3K inhibitors developed by Bayer Schering Pharma

Researchers at Celgene report new inhibitors of mutant EGFR

Spanish researchers prepare novel stable atomic quantum clusters

Merck & Co. discloses preclinical activity and structure of antimalarial drug candidate

Novel S1P1 receptor agonists discovered by Bristol-Myers Squibb

U.S. team presents new products for cancer and other disorders

Chugai to launch Pulmozyme in Japan

Neovacs reports interim results from trial of TNF-alpha kinoid

First-in-human trial of LY-2228820 completed

Hybrigenics reports first results from trial of oral inecalcitol in psoriasis

Oragenics and Intrexon form exclusive collaboration for lantibiotics

Affymetrix and Massachusetts General Hospital launch research collaboration

First-in-patient trial evaluates GSK-2256098

Long-term study of Contrave begins enrollment

Acquisition of ISTA Pharmaceuticals completed

FDA committee schedules meeting for ThromboGenics BLA

Alize Pharma raises funds to advance AZP-531

Celgene updates on Abraxane in multiple cancer indications

Enrollment complete in phase III PREVAIL study

Telormedix and Foamix receive funding to develop new topical skin cancer treatment

Rhythm Pharmaceuticals commences phase II study of ghrelin analogue

OxThera resumes development of treatment for primary hyperoxaluria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...